This inventor holds 1 USPTO granted patent. Top assignee: Boehringer Ingelheim Gmbh. Active years: 1976.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1976
Title: Innovator Klaus Minck: Pioneering Benzodiazepine Compounds
Introduction
Klaus Minck is a noteworthy inventor based in Gau-Algesheim, Germany. He holds a patent that contributes to the field of medicinal chemistry, specifically focusing on the development of benzodiazepine compounds.
Latest Patents
Minck's patent, titled "2-Amino-5-phenyl-4H-3,5-dihydro-1,5-benzodiazepin-4-ones and salts," presents novel compounds characterized by the formula ##SPC1##. This innovation aims to enhance the efficacy of benzodiazepines, which are widely used in therapeutic applications.
Career Highlights
Klaus Minck is associated with Boehringer Ingelheim GmbH, a leading global pharmaceutical company known for its commitment to research and innovation. His work at the company highlights his dedication to advancing drug development and improving patient outcomes.
Collaborations
Throughout his career, Minck has collaborated with esteemed colleagues, including Adolf Bauer and Karl H Weber. These professional partnerships have enabled fruitful exchanges of ideas and expertise within the pharmaceutical field, fostering a collaborative environment that ultimately benefits innovation.
Conclusion
Klaus Minck's contributions to the pharmaceutical industry, particularly through his patent on benzodiazepine compounds, exemplify the important role of inventors in advancing healthcare solutions. His work at Boehringer Ingelheim GmbH and collaborations with other innovators reinforce the significance of teamwork and research in driving pharmaceutical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile